{"commentary":{"count":7,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4,"youtube":2,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"DB-07","nct_id":"NCT04538742","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=db-07-nct04538742. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"DB-07","arms":[{"description":"T-DXd and Durvalumab","label":"Module 1- T-DXd and Durvalumab","type":"EXPERIMENTAL"},{"description":"T-DXd and Pertuzumab","label":"Module 2- T-DXd and Pertuzumab","type":"EXPERIMENTAL"},{"description":"T-DXd and Paclitaxel (Arm not initiated in Part 2)","label":"Module 3- T-DXd and Paclitaxel","type":"EXPERIMENTAL"},{"description":"T-DXd and Durvalumab and Paclitaxel (Arm not initiated in Part 1 and Part 2)","label":"Module 4- T-DXd and Durvalumab and Paclitaxel","type":"EXPERIMENTAL"},{"description":"T-DXd","label":"Module 0- T-DXd","type":"EXPERIMENTAL"},{"description":"T-DXd and tucatinib (Arm not initiated in Part 2)","label":"Module 5 - T-DXd and Tucatanib","type":"EXPERIMENTAL"},{"description":"T-DXd and tucatinib in patients with active brain metastases (Part 2 Only) (Arm not initiated)","label":"Module 6 - T-DXd and Tucatinib","type":"EXPERIMENTAL"},{"description":"T-DXd monotherapy in patients with active brain metastases (Part 2 Only)","label":"Module 7 - T-DXd","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo Company, Limited"],"completion_date":{"date":"2030-01-31","type":"ESTIMATED"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":245,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Pertuzumab","type":"DRUG"},{"name":"Tucatinib","type":"DRUG"}],"last_update":"2025-12-08","lead_sponsor":"AstraZeneca","official_title":"A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-01-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Occurrence of adverse events (AEs)- Part 1","timeFrame":"Up to follow-up period, approximately 53 months"},{"measure":"Occurrence of serious adverse events (SAEs)- Part 1","timeFrame":"Up to follow-up period, approximately 53 months"},{"measure":"Occurrence of adverse events (AEs)- Part 2","timeFrame":"Up to follow-up period, approximately 53 months"},{"measure":"Occurrence of serious adverse events (SAEs)- Part 2","timeFrame":"Up to follow-up period, approximately 53 months"}],"references":[],"start_date":{"date":"2020-12-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04538742"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/db-07-nct04538742"}